Author

M. Aladjem

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:DNA methylation· 1 Approach:experimental assay· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

A. Thomas· 2 shared R. Sebastian· 2 shared Y. Pommier· 2 shared A. Luna· 1 shared A. Zimmermann· 1 shared B. Elenbaas· 1 shared B. Teicher· 1 shared C. Tlemsani· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Thomas

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ATR inhibition augments the efficacy of lurbinectedin in small cell lung cancer

C. W. Schultz, Y. Zhang, R. Elmeskini, A. Zimmermann, H. Fu, Y. Murai, D. Wangsa, S. Kumar, N. Takahashi, D. Atkinson, L. K. Saha, C.-F. Lee, B. Elenbaas, P. Desai, R. Sebastian, , A. Thomas

This study shows that combining ATR inhibition with lurbinectedin improves efficacy in SCLC, particularly in MYC-driven non-neuroendocrine tumors.

EMBO Molecular Medicine · Aug 7, 2023Peer-reviewedCancer Biology

SCLC_CellMiner: Integrated Genomics and Therapeutics Predictors of Small Cell Lung Cancer Cell Lines based on their genomic signatures

C. Tlemsani, L. Pongor, L. Girard, N. Roper, F. Elloumi, S. Varma, A. Luna, V. N. Rajapakse, R. Sebastian, K. W. Kohn, J. Krushkal, M. Aladjem, B. Teicher, P. S. Meltzer, W. C. Reinhold, , Y. Pommier

SCLC_CellMiner provides an integrated resource of 118 SCLC cell lines with omics data and drug sensitivity, identifying molecular subtypes and therapeutic targets.

bioRxiv · Mar 9, 2020 · PreprintCancer Biology